Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Preclinical Characterization of Antitumor Activity of IPH6501, a First-in-Class IL2v-Armed Tetraspecific NK Cell Engager Directed Against CD20, and Comparison with Approved CD20-Targeting Therapies

Blood (2024) 144 (Supplement 1): 5824.

https://doi.org/10.1182/blood-2024-201502

Published: 2024

Journal Articles

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Olivier Demaria, Guillaume Habif, François Le Floch, Laura Chiossone, Romain Remark, Marie Vetizou, Nadia Maurel, Laurent Gauthier, Yannis Morel, Carine Paturel, Eric Vivier, Pascale Andre

Blood (2022) 140 (Supplement 1): 11559.

https://doi.org/10.1182/blood-2022-163561

Published: 2022

Journal Articles

The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Alexandre Tang, Laurent Gauthier, Jochen Beninga, Benjamin Rossi, Nicolas Gourdin, Audrey Blanchard-Alvarez, Céline Amara, Jacqueline Courta, Alexandra Basset, Dorothee Bourges, Alexandre Desjonqueres, Emmanuelle Menoret, Catherine Pellat-Deceunynck, Philippe Moreau, Yannis Morel, Marielle Chiron, Angela Virone-Oddos, Eric Vivier

Blood (2022) 140 (Supplement 1): 9985–9986.

https://doi.org/10.1182/blood-2022-166187

Published: 2022

Journal Articles

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

Raynier Devillier, Sabine Furst, Agnes boyer Chammard, Thomas Pagliardini, Samia Harbi, Valerio Maisano, Angela Granata, Faezeh Legrand, Jihane Pakradouni, jean Marie Boher, Cyril Fauriat, Anne-Sophie Chretien, Christian Chabannon, Norbert Vey, Eric Vivier, Daniel Olive, Didier Blaise

Blood (2021) 138 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2021-150730

Published: 2021

Journal Articles

Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Raynier Devillier, Boris Calmels, Pharm.D., Sophie Guia, Cyril Fauriat, Sabine Furst, Samia Harbi, Angela Granata, MD, Sophie Ugolini, Christian Chabannon, MD PhD, Daniel Olive, MD PhD, Eric Vivier, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140753

Published: 2020

Journal Articles

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Holbrook E. Kohrt, Ariane Thielens, Aurelien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, Eric Vivier, François Romagné, Ronald Levy, Mathieu Bléry, Pascale André

Blood (2014) 123 (5): 678–686.

https://doi.org/10.1182/blood-2013-08-519199

Published: 2014

Includes: Supplemental data

Journal Articles

Altered distribution and function of natural killer cells in murine and human Niemann-Pick disease type C1

Blood (2014) 123 (1): 51–60.

https://doi.org/10.1182/blood-2013-03-488692

Published: 2014

Includes: Supplemental data

Journal Articles

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Holbrook E Kohrt, MD, PhD, Ariane Thielens, Aurelien Marabelle, MD, MSc, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, PhD, Eric Vivier, PhD, Francois Romagne, PhD, Ronald Levy, MD, Pascale Andre, PhD, Mathieu Blery, PhD

Blood (2013) 122 (21): 4417.

https://doi.org/10.1182/blood.V122.21.4417.4417

Published: 2013

Journal Articles

Induction of B7-H6, a ligand for the natural killer cell–activating receptor NKp30, in inflammatory conditions

Jessica Matta, Myriam Baratin, Laurent Chiche, Jean-Marie Forel, Céline Cognet, Guillemette Thomas, Catherine Farnarier, Christelle Piperoglou, Laurent Papazian, Damien Chaussabel, Sophie Ugolini, Frédéric Vély, Eric Vivier

Blood (2013) 122 (3): 394–404.

https://doi.org/10.1182/blood-2013-01-481705

Published: 2013

Includes: Supplemental data

Journal Articles

Impact of β2 integrin deficiency on mouse natural killer cell development and function

Karine Crozat, Céline Eidenschenk, Baptiste N. Jaeger, Philippe Krebs, Sophie Guia, Bruce Beutler, Eric Vivier, Sophie Ugolini

Blood (2011) 117 (10): 2874–2882.

https://doi.org/10.1182/blood-2010-10-315457

Published: 2011

Includes: Supplemental data

Journal Articles

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Francois Romagné, Pascale André, Pieter Spee, Stefan Zahn, Nicolas Anfossi, Laurent Gauthier, Marusca Capanni, Loredana Ruggeri, Don M. Benson, Jr, Bradley W. Blaser, Mariella Della Chiesa, Alessandro Moretta, Eric Vivier, Michael A. Caligiuri, Andrea Velardi, Nicolai Wagtmann

Blood (2009) 114 (13): 2667–2677.

https://doi.org/10.1182/blood-2009-02-206532

Published: 2009

Includes: Supplemental data

Journal Articles

Maturation of mouse NK cells is a 4-stage developmental program

Laura Chiossone, Julie Chaix, Nicolas Fuseri, Claude Roth, Eric Vivier, Thierry Walzer

Blood (2009) 113 (22): 5488–5496.

https://doi.org/10.1182/blood-2008-10-187179

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

Daniela Pende, Stefania Marcenaro, Michela Falco, Stefania Martini, Maria Ester Bernardo, Daniela Montagna, Elisa Romeo, Céline Cognet, Miryam Martinetti, Rita Maccario, Maria Cristina Mingari, Eric Vivier, Lorenzo Moretta, Franco Locatelli, Alessandro Moretta

Blood (2009) 113 (13): 3119–3129.

https://doi.org/10.1182/blood-2008-06-164103

Published: 2009

Includes: Supplemental data

Journal Articles

A role for interleukin-12/23 in the maturation of human natural killer and CD56 + T cells in vivo

Sophie Guia, Céline Cognet, Ludovic de Beaucoudrey, Marlowe S. Tessmer, Emmanuelle Jouanguy, Claire Berger, Orchidée Filipe-Santos, Jacqueline Feinberg, Yildiz Camcioglu, Jacob Levy, Suliman Al Jumaah, Sami Al-Hajjar, Jean-Louis Stephan, Claire Fieschi, Laurent Abel, Laurent Brossay, Jean-Laurent Casanova, Eric Vivier

Blood (2008) 111 (10): 5008–5016.

https://doi.org/10.1182/blood-2007-11-122259

Published: 2008

Includes: Supplemental data

Journal Articles

Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways

Jérôme D. Coudert, Léonardo Scarpellino, Frédéric Gros, Eric Vivier, Werner Held

Blood (2008) 111 (7): 3571–3578.

https://doi.org/10.1182/blood-2007-07-100057

Published: 2008

Includes: Supplemental data

Journal Articles

Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses

Shlomo Nedvetzki, Stefanie Sowinski, Robert A. Eagle, James Harris, Frédéric Vély, Daniela Pende, John Trowsdale, Eric Vivier, Siamon Gordon, Daniel M. Davis

Blood (2007) 109 (9): 3776–3785.

https://doi.org/10.1182/blood-2006-10-052977

Published: 2007

Includes: Supplemental data

Journal Articles

Tolerogenic dendritic cells: a KARAP/DAP12–IRF-8/ICSBP balance

Eric Vivier, Marc Dalod

Blood (2006) 107 (7): 2591–2592.

https://doi.org/10.1182/blood-2006-01-0229

Published: 2006

Journal Articles

Multiplicity and plasticity of natural killer cell signaling pathways

Sabrina Chiesa, Michael Mingueneau, Nicolas Fuseri, Bernard Malissen, David H. Raulet, Marie Malissen, Eric Vivier, Elena Tomasello

Blood (2006) 107 (6): 2364–2372.

https://doi.org/10.1182/blood-2005-08-3504

Published: 2006

Includes: Supplemental data

Journal Articles

Natural-killer cells and dendritic cells: “l'union fait la force”

Thierry Walzer, Marc Dalod, Scott H. Robbins, Laurence Zitvogel, Eric Vivier

Blood (2005) 106 (7): 2252–2258.

https://doi.org/10.1182/blood-2005-03-1154

Published: 2005

Journal Articles

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand–expressing tumor cells

Jérôme D. Coudert, Jacques Zimmer, Elena Tomasello, Marek Cebecauer, Marco Colonna, Eric Vivier, Werner Held

Blood (2005) 106 (5): 1711–1717.

https://doi.org/10.1182/blood-2005-03-0918

Published: 2005

NARROW

Preclinical Characterization of Antitumor Activity of IPH6501, a First-in-Class IL2v-Armed Tetraspecific NK Cell Engager Directed Against CD20, and Comparison with Approved CD20-Targeting Therapies

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study

Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Altered distribution and function of natural killer cells in murine and human Niemann-Pick disease type C1

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Induction of B7-H6, a ligand for the natural killer cell–activating receptor NKp30, in inflammatory conditions

Impact of β2 integrin deficiency on mouse natural killer cell development and function

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Maturation of mouse NK cells is a 4-stage developmental program

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

A role for interleukin-12/23 in the maturation of human natural killer and CD56 + T cells in vivo

Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways

Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses

Tolerogenic dendritic cells: a KARAP/DAP12–IRF-8/ICSBP balance

Multiplicity and plasticity of natural killer cell signaling pathways

Natural-killer cells and dendritic cells: “l'union fait la force”

Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand–expressing tumor cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only